TrialThe Journal of infectious diseases2017

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Julien Nyombayire et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.